Norman Robert, Greenberg Robert G, Jackson J Mark
J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S139-42. doi: 10.1016/j.jaad.2005.11.1090.
Skin disfigurations and pruritus can pose severe threats to quality of life, and treatment options for patients with recalcitrant diseases are limited. Tumor necrosis factor alpha, a proinflammatory cytokine, appears to play a central role in mediating the symptoms of many skin disorders. We report cases in which etanercept (Enbrel; Immunex Corp, Thousand Oaks, Calif), a tumor necrosis factor alpha antagonist that is approved for the treatment of moderate to severe psoriasis, was administered to ameliorate the symptoms of acute and chronic dermatologic conditions, including Hailey-Hailey disease, severe psoriasis, dermatomyositis, and subacute cutaneous lupus erythematosus. Treatment with etanercept substantially improved the clinical symptoms and quality of life in these patients, and may offer a therapeutic option for some patients with severe skin disorders.
皮肤毁容和瘙痒会对生活质量构成严重威胁，而针对顽固性疾病患者的治疗选择有限。肿瘤坏死因子α是一种促炎细胞因子，似乎在介导许多皮肤疾病的症状中起核心作用。我们报告了一些病例，其中使用已被批准用于治疗中度至重度银屑病的肿瘤坏死因子α拮抗剂依那西普（恩利；免疫ex公司，加利福尼亚州千橡市）来改善急性和慢性皮肤病的症状，包括黑利-黑利病、重度银屑病、皮肌炎和亚急性皮肤型红斑狼疮。依那西普治疗显著改善了这些患者的临床症状和生活质量，并且可能为一些患有严重皮肤病的患者提供一种治疗选择。
